Logo - springer
Slogan - springer

| Drug Safety - Case Reports

Drug Safety - Case Reports

Drug Safety - Case Reports

Editors: N. Joshi; S. McMillan

ISSN: 2198-977X (electronic version)

Journal no. 40800

Instructions for Authors

General Information 

Adverse Event Reporting Guidelines

The journal requests that the reporting of cases follows current best practice. Authors are advised to adhere to the Guidelines for Submitting Adverse Event Reports for Publication. These guidelines are published in Drug Safety 2007; 30 (5):367-373, and are freely available here:
In accordance with these guidelines, the journal does not specify a word limit for submissions.

Manuscript Submission 

Manuscript Submission

Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.

Permissions

Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.

Online Submission

Please follow the hyperlink “Submit online” on the right and upload all of your manuscript files following the instructions given on the screen.

Title page 

Title Page

The title page should include:
  • The name(s) of the author(s)
  • A concise and informative title
  • The affiliation(s) and address(es) of the author(s)
  • The e-mail address, and telephone number(s) of the corresponding author
  • If available, the 16-digit ORCID of the author(s)

Abstract

Please provide an abstract of 150 to 250 words. The abstract should not contain any undefined abbreviations or unspecified references.

Please note:

Please note that, for some articles (particularly, systematic reviews and original research articles), 250 words may not be sufficient to provide all necessary information in the abstract. Therefore, the abstract length can be increased from the 250-word limit (to up to 450 words) if the topic dictates, and to allow full compliance with the relevant reporting guidelines.
If several cases are being reported, please ensure that you indicate in the abstract which patients took which drugs and had which reactions.
Required information
Please include the below information in your abstract.
1. Suspect drug name
Generic names of drugs are preferred; and if brand names are used, the generic name should be given at first mention.
2. Suspect drug dosage
Dosage includes the dose, frequency and route of administration. Include all the dosing information, e.g. if the dosage changes over time
3. Suspect drug indication
Please make it explicit what indication the suspect drug was being taken for
4. Duration of therapy/time to reaction onset
All information regarding the time frame from when the suspect drug was started until the onset of the reaction must be included. If the patient had previously received the drug, then also include this information.
5. Age and sex of patient
Age should refer to the patient’s age at reaction onset.
6. Reaction description
Give a description of the reaction, including the presenting symptoms. Include the main/relevant laboratory investigations that led to diagnosis of the reaction
Provide a full diagnosis and/or detail of the adverse drug reaction(s).
7. Outcome (+ treatment given)
Please include details of the patient’s status at the last follow-up.
8. Causality
Conclude your abstract with any information regarding assessment of causality (e.g. Naranjo scale assessment) and/or information regarding the mechanisms behind the adverse drug reaction.
Additional information
You may wish to include other information in the abstract, such as the following, if considered relevant.
1. Concomitant/previous medications
2. Diseases other than the indication
3. Test results

Narrative template for the abstract of a case report

An x-year-old man/woman developed [suspect ADR] during treatment with [drug] for [indication]. The man/woman received [drug] at [dosage] for [indication]. After [time period] he/she developed [signs and symptoms]. Investigations revealed the following [results details]. He/she was diagnosed with [adverse drug reaction]. [Drug] was discontinued and the patient received [treatment]. The patient had [outcome] after [time period]. A Naranjo assessment score of n was obtained, indicating a definite/probable/possible relationship between the patient's [symptoms/ADR] and his/her use of the suspect drug.

Text 

Text Formatting

Manuscripts should be submitted in Word.
  • Use a normal, plain font (e.g., 10-point Times Roman) for text.
  • Use italics for emphasis.
  • Use the automatic page numbering function to number the pages.
  • Do not use field functions.
  • Use tab stops or other commands for indents, not the space bar.
  • Use the table function, not spreadsheets, to make tables.
  • Use the equation editor or MathType for equations.
  • Save your file in docx format (Word 2007 or higher) or doc format (older Word versions).
Manuscripts with mathematical content can also be submitted in LaTeX.

Headings

Please use the decimal system of headings with no more than three levels.

Abbreviations

Abbreviations should be defined at first mention and used consistently thereafter.

Footnotes

Footnotes can be used to give additional information, which may include the citation of a reference included in the reference list. They should not consist solely of a reference citation, and they should never include the bibliographic details of a reference. They should also not contain any figures or tables.
Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data). Footnotes to the title or the authors of the article are not given reference symbols.
Always use footnotes instead of endnotes.

Acknowledgments

Acknowledgments of people, grants, funds, etc. should be placed in a separate section on the title page. The names of funding organizations should be written in full.

Scientific style  

  • Please always use internationally accepted signs and symbols for units (SI units).
  • Nomenclature: Insofar as possible, authors should use systematic names similar to those used by Chemical Abstract Service or IUPAC.
  • Genus and species names should be in italics.
  • Generic names of drugs and pesticides are preferred; if trade names are used, the generic name should be given at first mention.
  • Please use the standard mathematical notation for formulae, symbols, etc.:
    Italic for single letters that denote mathematical constants, variables, and unknown quantities
    Roman/upright for numerals, operators, and punctuation, and commonly defined functions or abbreviations, e.g., cos, det, e or exp, lim, log, max, min, sin, tan, d (for derivative)
    Bold for vectors, tensors, and matrices.

References 

Citation

Reference citations in the text should be identified by numbers in square brackets. Some examples:
1. Negotiation research spans many disciplines [3].
2. This result was later contradicted by Becker and Seligman [5].
3. This effect has been widely studied [1-3, 7].

Reference list

The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text. Do not use footnotes or endnotes as a substitute for a reference list.
The entries in the list should be numbered consecutively.
  • Journal article
    Smith JJ. The world of science. Am J Sci. 1999;36:234–5.
  • Article by DOI
    Slifka MK, Whitton JL. Clinical implications of dysregulated cytokine production. J Mol Med. 2000; https://doi.org/10.1007/s001090000086
  • Book
    Blenkinsopp A, Paxton P. Symptoms in the pharmacy: a guide to the management of common illness. 3rd ed. Oxford: Blackwell Science; 1998.
  • Book chapter
    Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. In: Bourne GH, Danielli JF, Jeon KW, editors. International review of cytology. London: Academic; 1980. pp. 251–306.
  • Online document
    Doe J. Title of subordinate document. In: The dictionary of substances and their effects. Royal Society of Chemistry. 1999. http://www.rsc.org/dose/title of subordinate document. Accessed 15 Jan 1999.
Always use the standard abbreviation of a journal’s name according to the ISSN List of Title Word Abbreviations, see
If you are unsure, please use the full journal title.
For authors using EndNote, Springer provides an output style that supports the formatting of in-text citations and reference list.

Tables 

  • All tables are to be numbered using Arabic numerals.
  • Tables should always be cited in text in consecutive numerical order.
  • For each table, please supply a table caption (title) explaining the components of the table.
  • Identify any previously published material by giving the original source in the form of a reference at the end of the table caption.
  • Footnotes to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data) and included beneath the table body.

Artwork and Illustrations Guidelines 

Electronic Figure Submission

  • Supply all figures electronically.
  • Indicate what graphics program was used to create the artwork.
  • For vector graphics, the preferred format is EPS; for halftones, please use TIFF format. MSOffice files are also acceptable.
  • Vector graphics containing fonts must have the fonts embedded in the files.
  • Name your figure files with "Fig" and the figure number, e.g., Fig1.eps.

Line Art

Line BW
  • Definition: Black and white graphic with no shading.
  • Do not use faint lines and/or lettering and check that all lines and lettering within the figures are legible at final size.
  • All lines should be at least 0.1 mm (0.3 pt) wide.
  • Scanned line drawings and line drawings in bitmap format should have a minimum resolution of 1200 dpi.
  • Vector graphics containing fonts must have the fonts embedded in the files.

Halftone Art

Halftone gray color
  • Definition: Photographs, drawings, or paintings with fine shading, etc.
  • If any magnification is used in the photographs, indicate this by using scale bars within the figures themselves.
  • Halftones should have a minimum resolution of 300 dpi.

Combination Art

Combined
  • Definition: a combination of halftone and line art, e.g., halftones containing line drawing, extensive lettering, color diagrams, etc.
  • Combination artwork should have a minimum resolution of 600 dpi.

Color Art

  • Color art is free of charge for online publication.
  • If black and white will be shown in the print version, make sure that the main information will still be visible. Many colors are not distinguishable from one another when converted to black and white. A simple way to check this is to make a xerographic copy to see if the necessary distinctions between the different colors are still apparent.
  • If the figures will be printed in black and white, do not refer to color in the captions.
  • Color illustrations should be submitted as RGB (8 bits per channel).

Figure Lettering

  • To add lettering, it is best to use Helvetica or Arial (sans serif fonts).
  • Keep lettering consistently sized throughout your final-sized artwork, usually about 2–3 mm (8–12 pt).
  • Variance of type size within an illustration should be minimal, e.g., do not use 8-pt type on an axis and 20-pt type for the axis label.
  • Avoid effects such as shading, outline letters, etc.
  • Do not include titles or captions within your illustrations.

Figure Numbering

  • All figures are to be numbered using Arabic numerals.
  • Figures should always be cited in text in consecutive numerical order.
  • Figure parts should be denoted by lowercase letters (a, b, c, etc.).
  • If an appendix appears in your article and it contains one or more figures, continue the consecutive numbering of the main text. Do not number the appendix figures,
    "A1, A2, A3, etc." Figures in online appendices (Electronic Supplementary Material) should, however, be numbered separately.

Figure Captions

  • Each figure should have a concise caption describing accurately what the figure depicts. Include the captions in the text file of the manuscript, not in the figure file.
  • Figure captions begin with the term Fig. in bold type, followed by the figure number, also in bold type.
  • No punctuation is to be included after the number, nor is any punctuation to be placed at the end of the caption.
  • Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as coordinate points in graphs.
  • Identify previously published material by giving the original source in the form of a reference citation at the end of the figure caption.

Figure Placement and Size

  • Figures should be submitted separately from the text, if possible.
  • When preparing your figures, size figures to fit in the column width.
  • For most journals the figures should be 39 mm, 84 mm, 129 mm, or 174 mm wide and not higher than 234 mm.
  • For books and book-sized journals, the figures should be 80 mm or 122 mm wide and not higher than 198 mm.

Permissions

If you include figures that have already been published elsewhere, you must obtain permission from the copyright owner(s) for both the print and online format. Please be aware that some publishers do not grant electronic rights for free and that Springer will not be able to refund any costs that may have occurred to receive these permissions. In such cases, material from other sources should be used.

Accessibility

In order to give people of all abilities and disabilities access to the content of your figures, please make sure that
  • All figures have descriptive captions (blind users could then use a text-to-speech software or a text-to-Braille hardware)
  • Patterns are used instead of or in addition to colors for conveying information (colorblind users would then be able to distinguish the visual elements)
  • Any figure lettering has a contrast ratio of at least 4.5:1

Electronic Supplementary Material 

Springer accepts electronic multimedia files (animations, movies, audio, etc.) and other supplementary files to be published online along with an article or a book chapter. This feature can add dimension to the author's article, as certain information cannot be printed or is more convenient in electronic form.
Before submitting research datasets as electronic supplementary material, authors should read the journal’s Research data policy. We encourage research data to be archived in data repositories wherever possible.

Submission

  • Supply all supplementary material in standard file formats.
  • Please include in each file the following information: article title, journal name, author names; affiliation and e-mail address of the corresponding author.
  • To accommodate user downloads, please keep in mind that larger-sized files may require very long download times and that some users may experience other problems during downloading.

Audio, Video, and Animations

  • Aspect ratio: 16:9 or 4:3
  • Maximum file size: 25 GB
  • Minimum video duration: 1 sec
  • Supported file formats: avi, wmv, mp4, mov, m2p, mp2, mpg, mpeg, flv, mxf, mts, m4v, 3gp

Text and Presentations

  • Submit your material in PDF format; .doc or .ppt files are not suitable for long-term viability.
  • A collection of figures may also be combined in a PDF file.

Spreadsheets

  • Spreadsheets should be submitted as .csv or .xlsx files (MS Excel).

Specialized Formats

  • Specialized format such as .pdb (chemical), .wrl (VRML), .nb (Mathematica notebook), and .tex can also be supplied.

Collecting Multiple Files

  • It is possible to collect multiple files in a .zip or .gz file.

Numbering

  • If supplying any supplementary material, the text must make specific mention of the material as a citation, similar to that of figures and tables.
  • Refer to the supplementary files as “Online Resource”, e.g., "... as shown in the animation (Online Resource 3)", “... additional data are given in Online Resource 4”.
  • Name the files consecutively, e.g. “ESM_3.mpg”, “ESM_4.pdf”.

Captions

  • For each supplementary material, please supply a concise caption describing the content of the file.

Processing of supplementary files

  • Electronic supplementary material will be published as received from the author without any conversion, editing, or reformatting.

Accessibility

In order to give people of all abilities and disabilities access to the content of your supplementary files, please make sure that
  • The manuscript contains a descriptive caption for each supplementary material
  • Video files do not contain anything that flashes more than three times per second (so that users prone to seizures caused by such effects are not put at risk)

Research Data Policy 

A submission to the journal implies that materials described in the manuscript, including all relevant raw data, will be freely available to any researcher wishing to use them for non-commercial purposes, without breaching participant confidentiality.
The journal strongly encourages that all datasets on which the conclusions of the paper rely should be available to readers. We encourage authors to ensure that their datasets are either deposited in publicly available repositories (where available and appropriate) or presented in the main manuscript or additional supporting files whenever possible. Please see Springer Nature’s information on recommended repositories.
General repositories - for all types of research data - such as figshare and Dryad may be used where appropriate.
Datasets that are assigned digital object identifiers (DOIs) by a data repository may be cited in the reference list. Data citations should include the minimum information recommended by DataCite: authors, title, publisher (repository name), identifier.
Where a widely established research community expectation for data archiving in public repositories exists, submission to a community-endorsed, public repository is mandatory. Persistent identifiers (such as DOIs and accession numbers) for relevant datasets must be provided in the paper
For the following types of data set, submission to a community-endorsed, public repository is mandatory:
Mandatory depositionSuitable repositories
Protein sequencesUniprot
DNA and RNA sequencesGenbank
DNA DataBank of Japan (DDBJ)
EMBL Nucleotide Sequence Database (ENA)
DNA and RNA sequencing dataNCBI Trace Archive
NCBI Sequence Read Archive (SRA)
Genetic polymorphismsdbSNP
dbVar
European Variation Archive (EVA)
Linked genotype and phenotype datadbGAP
The European Genome-phenome Archive (EGA)
Macromolecular structureWorldwide Protein Data Bank (wwPDB)
Biological Magnetic Resonance Data Bank (BMRB)
Electron Microscopy Data Bank (EMDB)
Microarray data (must be MIAME compliant)Gene Expression Omnibus (GEO)
ArrayExpress
Crystallographic data for small moleculesCambridge Structural Database

Data availability

The journal encourages authors to provide a statement of Data availability in their article. Data availability statements should include information on where data supporting the results reported in the article can be found, including, where applicable, hyperlinks to publicly archived datasets analysed or generated during the study. Data availability statements can also indicate whether data are available on request from the authors and where no data are available, if appropriate.
Data Availability statements can take one of the following forms (or a combination of more than one if required for multiple datasets):
  • 1. The datasets generated during and/or analysed during the current study are available in the [NAME] repository, [PERSISTENT WEB LINK TO DATASETS]
  • 2. The datasets generated during and/or analysed during the current study are not publicly available due [REASON WHY DATA ARE NOT PUBLIC] but are available from the corresponding author on reasonable request.
  • 3. The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
  • 4. Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
  • 5. All data generated or analysed during this study are included in this published article [and its supplementary information files].
More examples of template data availability statements, which include examples of openly available and restricted access datasets, are available:
This service provides advice on research data policy compliance and on finding research data repositories. It is independent of journal, book and conference proceedings editorial offices and does not advise on specific manuscripts.

Copyright 

In confirming the publication of your article with open access you agree to the Creative Commons Attribution Non-Commercial License 4.0 International License

Offprints

Offprints can be ordered by the corresponding author.

Colour illustrations

Online publication of colour illustrations is free of charge.

Proof reading

The purpose of the proof is to check for typesetting or conversion errors and the completeness and accuracy of the text, tables and figures. Substantial changes in content, e.g., new results, corrected values, title and authorship, are not allowed without the approval of the Editor.
After online publication, further changes can only be made in the form of an Erratum, which will be hyperlinked to the article.

Online Publication

Articles will be published online after receipt of the corrected proofs. Articles will be published with their final citation, in both fully browsable web form, and as a formatted PDF.

Integrity of Research and Reporting 

General

Adis journals endorse the ‘Uniform Requirements for Manuscripts Submitted to Biomedical Journals,’ issued by the International Committee for Medical Journal Editors (see link below) and are members of the Committee on Publication Ethics (see link below).

Disclosure of potential conflicts of interest 

Authors must disclose all relationships or interests that could influence or bias the work. Although an author may not feel there are conflicts, disclosure of relationships and interests affords a more transparent process, leading to an accurate and objective assessment of the work. Awareness of real or perceived conflicts of interests is a perspective to which the readers are entitled and is not meant to imply that a financial relationship with an organization that sponsored the research or compensation for consultancy work is inappropriate. Examples of potential conflicts of interests that are directly or indirectly related to the research may include but are not limited to the following:
  • Research grants from funding agencies (please give the research funder and the grant number)
  • Honoraria for speaking at symposia
  • Financial support for attending symposia
  • Financial support for educational programs
  • Employment or consultation
  • Support from a project sponsor
  • Position on advisory board or board of directors or other type of management relationships
  • Multiple affiliations
  • Financial relationships, for example equity ownership or investment interest
  • Intellectual property rights (e.g. patents, copyrights and royalties from such rights)
  • Holdings of spouse and/or children that may have financial interest in the work
In addition, interests that go beyond financial interests and compensation (non-financial interests) that may be important to readers should be disclosed. These may include but are not limited to personal relationships or competing interests directly or indirectly tied to this research, or professional interests or personal beliefs that may influence your research.
The corresponding author collects the conflict of interest disclosure forms from all authors. (Please note that each author should complete a disclosure form.)
Please make sure to submit all Conflict of Interest disclosure forms together with the manuscript.
See below examples of disclosures:
Funding: This study was funded by X (grant number X).
Conflict of Interest: Author A has received research grants from Company A. Author B has received a speaker honorarium from Company X and owns stock in Company Y. Author C is a member of committee Z.
If no conflict exists, the authors should state:
Conflict of Interest: Author A, Author B, and Author C declare that they have no conflict of interest.

Consent 

Patients must have given their written informed consent for the case report and any accompanying images to be published, and this consent must be mentioned in the case report. We recommend the following wording is used for the consent section: "Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent may be requested for review from the corresponding author."
If the person described in the case report has died, then consent for publication must be sought from their next of kin.

Use of Personal Communications and Unpublished Data 

Authors must include a signed statement of permission from each individual identified as a source of information in a personal communication or as a source for unpublished data (this includes papers that have been submitted, but not yet accepted for publication), and specify the date of communication and whether the communication was written or oral.

Duplicate Publication and Duplicate Submission 

Manuscripts are considered with the understanding that they have not been published previously and are not under consideration by another publication. Copies of possibly duplicative materials (i.e. those containing substantially similar content or using the same or similar data) that have been previously published or are being considered elsewhere must be provided at the time of manuscript submission. Submitted or published manuscripts that are found to be duplicated in any substantive way will be followed up and responded to in accordance with the guidelines of the Committee on Publication Ethics (see link below).
The journal will, however, consider republication of a paper previously published in a language other than English, or simultaneous publication of a paper in multiple journals with different audiences, if the specific circumstances warrant this action. This will be done with full and prominent disclosure of the original source and with any necessary permission. The journal does not consider posting of protocols and results in clinical trial registries to be prior publication. Press releases of studies presented at scientific meetings are also not considered prior publication and will not compromise an author’s ability to write up a full study provided the release does not disclose results beyond those presented in the meeting abstract or poster.

Plagiarism 

Plagiarism is the use of others' published and unpublished ideas or words (or other intellectual property) without attribution or permission, and presenting them as new and original rather than derived from an existing source. Plagiarism is scientific misconduct and will be addressed as such following the Committee on Publication Ethics guidelines (see link below).

English Language Editing 

For editors and reviewers to accurately assess the work presented in your manuscript you need to ensure the English language is of sufficient quality to be understood. If you need help with writing in English you should consider:
  • Asking a colleague who is a native English speaker to review your manuscript for clarity.
  • Visiting the English language tutorial which covers the common mistakes when writing in English.
  • Using a professional language editing service where editors will improve the English to ensure that your meaning is clear and identify problems that require your review. Two such services are provided by our affiliates Nature Research Editing Service and American Journal Experts. Springer authors are entitled to a 10% discount on their first submission to either of these services, simply follow the links below.
Please note that the use of a language editing service is not a requirement for publication in this journal and does not imply or guarantee that the article will be selected for peer review or accepted.
If your manuscript is accepted it will be checked by our copyeditors for spelling and formal style before publication.

.

为便于编辑和评审专家准确评估您稿件中陈述的研究工作,您需要确保您的英语语言质量足以令人理解。如果您需要英文写作方面的帮助,您可以考虑:
● 请一位以英语为母语的同事审核您的稿件是否表意清晰。
● 查看一些有关英语写作中常见语言错误的教程。
● 使用专业语言编辑服务,编辑人员会对英语进行润色,以确保您的意思表达清晰,并识别需要您复核的问题。我们的附属机构 Nature Research Editing Service 和合作伙伴 American Journal Experts 即可提供此类服务。
请注意,使用语言编辑服务并非在期刊上发表文章的必要条件,同时也并不意味或保证文章将被选中进行同行评议或被接受。
如果您的稿件被接受,在发表之前,我们的文字编辑会检查您的文稿拼写是否规范以及文体是否正式。

.

エディターと査読者があなたの論文を正しく評価するには、使用されている英語の質が十分に高いことが必要とされます。英語での論文執筆に際してサポートが必要な場合には、次のオプションがあります:
・英語を母国語とする同僚に、原稿で使用されている英語が明確であるかをチェックしてもらう。
・英語で執筆する際のよくある間違いに関する英語のチュートリアルを参照する。
・プロの英文校正サービスを利用する。校正者が原稿の意味を明確にしたり、問題点を指摘し、英語の質を向上させます。Nature Research Editing Service とAmerican Journal Experts の2つは弊社と提携しているサービスです。Springer の著者は、いずれのサービスも初めて利用する際には10%の割引を受けることができます。以下のリンクを参照ください。
英文校正サービスの利用は、投稿先のジャーナルに掲載されるための条件ではないこと、また論文審査や受理を保証するものではないことに留意してください。
原稿が受理されると、出版前に弊社のコピーエディターがスペルと体裁のチェックを行います。

.

영어 원고의 경우, 에디터 및 리뷰어들이 귀하의 원고에 실린 결과물을 정확하게 평가할 수 있도록, 그들이 충분히 이해할 수 있을 만한 수준으로 작성되어야 합니다. 만약 영작문과 관련하여 도움을 받기를 원하신다면 다음의 사항들을 고려하여 주십시오:
• 귀하의 원고의 표현을 명확히 해줄 영어 원어민 동료를 찾아서 리뷰를 의뢰합니다.
• 영어 튜토리얼 페이지에 방문하여 영어로 글을 쓸 때 자주하는 실수들을 확인합니다.
• 리뷰에 대비하여, 원고의 의미를 명확하게 해주고 리뷰에서 요구하는 문제점들을 식별해서 영문 수준을 향상시켜주는 전문 영문 교정 서비스를 이용합니다. Nature Research Editing Service와 American Journal Experts에서 저희와 협약을 통해 서비스를 제공하고 있습니다. Springer 저자들이 본 교정 서비스를 첫 논문 투고를 위해 사용하시는 경우 10%의 할인이 적용되며, 아래의 링크를 통하여 확인이 가능합니다.
영문 교정 서비스는 게재를 위한 요구사항은 아니며, 해당 서비스의 이용이 피어 리뷰에 논문이 선택되거나 게재가 수락되는 것을 의미하거나 보장하지 않습니다.
원고가 수락될 경우, 출판 전 저희측 편집자에 의해 원고의 철자 및 문체를 검수하는 과정을 거치게 됩니다.

EDITORIAL PROCEDURE 

Internal Review by Editorial Staff: The journal editor will perform an initial appraisal of each manuscript. If your paper has been peer reviewed by another journal as part of a prior submission, the journal editor will also assess any previous editorial/referee comments and how these have been dealt with as part of the appraisal process. If your manuscript is considered unsuitable for the journal to which it has been submitted, it may be assessed for suitability for publication in other Adis journals by appropriate editors. However, it will not be progressed to external peer review for an alternative journal without your permission.
External Peer Review: You will be notified as to whether your paper is progressing to external review, within 1 to 2 weeks of our acknowledgement of receipt. Peer reviewer identities are kept confidential, but author identities are known to the reviewers. Peer reviewers are asked to disclose potential conflicts of interests that may affect their ability to provide an unbiased review of an article. The majority of manuscripts will require some degree of revision following peer review before they can be accepted for publication. The final decision on acceptability for publication lies with the journal editor.
Copy Editing: All accepted manuscripts are copy edited. This process addresses general publishing considerations, such as layout of tables and figures, house style and clarity of expression. Authors will receive proofs following editing for their approval and sign off. It should be noted that the responsibility for checking the technical accuracy and consistency of data within the article rests with the authors.

For authors and editors

  • Aims and Scope

    Aims and Scope

    Close

    • Publishes case reports of individual and multiple patients experiencing adverse reactions to a wide range of medicinal products.
    • Reports include overdose, abuse, misuse, occupational exposure and more.
    • Also covers medication errors, off-label use and near-misses.
    • Articles published in Drug Safety - Case Reports may be accompanied by plain language summaries to assist patients, caregivers and others in their understanding.

    Drug Safety - Case Reports is an online, open access journal specialising in the publication of case reports and case series relating to suspected adverse drug reactions.  As well as reports of any unintended or adverse effects following administration of a medicinal product (or products), the journal welcomes reports of cases involving `near misses' (for example, medication errors detected before harm is done) and cases involving the lack of efficacy of a therapeutic product.

    Additional enhanced features (including slide sets, videos and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Drug Safety - Case Reports may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. All enhanced features are peer reviewed to the same high standard as the article itself.

    Upon acceptance for publication, manuscripts submitted to the journal will be subject to an article processing charge (APC) at an introductory price of US$1,095.  Adis Open Access enables you to make your journal article freely available to anyone, in exchange for payment of the APC. This option allows you, the author, to retain the copyright of the article according to the terms of the Creative Commons Attribution Non-Commercial (CCBY-NC) License, which does not permit commercial re-use of the article.

  • Submit Online
  • Instructions for Authors

    Instructions for Authors

    Close

  • Conflict of Interest form (doc, 84 kB)
  • Compliance with Ethical Policies
  • Copyright Information

    Copyright Information

    Close

    Copyright and Licence Agreement

    Open Access Drug Safety - Case Reports is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, go to: http://creativecommons. org/licenses/by-nc/4.0

    Journal ownership: Springer International Publishing Switzerland

    Copyright of articles: © The Author(s)

Alerts for this journal

 

Get the table of contents of every new issue published in Drug Safety - Case Reports.